Medicine
Rintu Sharma, Andree-Anne Pelland, K. Lajkosz, E. Masih-Khan, H. Vohra, S. Bhella, Christine I Chen, V. Kukreti, A. Stewart, S. Trudel, Chloe Yang, D. Reece, C. Venner, G. Lancman
2026.3.10Blood Cancer Discovery
Abstract
In this real-world study, debulking chemotherapy allows for high response rates to teclistamab in patients with relapsed/refractory multiple myeloma at high risk for primary resistance to teclistamab.
Citation format
SHARMA, Rintu, et al. Debulking chemotherapy can overcome primary resistance to teclistamab in relapsed/refractory multiple myeloma. Blood Cancer Discovery, 2026, 7(3): 394–402.